US 9339513
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
granted A61KA61K31/56A61K31/7088
Quick answer
US patent 9339513 (Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes) held by Alnylam Pharmaceuticals, Inc. expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 28
- CPC classes
- A61K, A61K31/56, A61K31/7088, A61K31/713, A61K45/06